The Recombinant Human Interleukin 2 Injection Market size is expected to grow at an annual average CAGR of 5% during 2022-2028. Recombinant human interleukin-2 (aldesleukin) and recombinant human interferon alpha can induce significant tumor regression in a limited number of patients with metastatic renal cell carcinoma. We performed a multicenter randomized trial to determine the […]
